<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nore KG</submitter><funding>Research Council Of Norway</funding><funding>University of Oslo</funding><funding>Oslo University Hospital</funding><funding>Olav Thon Foundation</funding><pagination>888-897</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10938220</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>229(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Current tuberculosis treatment regimens could be improved by adjunct host-directed therapies (HDT) targeting host responses. We investigated the antimycobacterial capacity of macrophages from patients with tuberculosis in a phase 1/2 randomized clinical trial (TBCOX2) of the cyclooxygenase-2 inhibitor etoricoxib.&lt;h4>Methods&lt;/h4>Peripheral blood mononuclear cells from 15 patients with tuberculosis treated with adjunctive COX-2i and 18 controls (standard therapy) were collected on day 56 after treatment initiation. The ex vivo capacity of macrophages to control mycobacterial infection was assessed by challenge with Mycobacterium avium, using an in vitro culture model. Macrophage inflammatory responses were analyzed by gene expression signatures, and concentrations of cytok</pubmed_abstract><journal>The Journal of infectious diseases</journal><pubmed_title>The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth.</pubmed_title><pmcid>PMC10938220</pmcid><funding_grant_id>234493</funding_grant_id><funding_grant_id>287696</funding_grant_id><funding_grant_id>223255</funding_grant_id><funding_grant_id>2017009</funding_grant_id><pubmed_authors>Bugge M</pubmed_authors><pubmed_authors>Flo TH</pubmed_authors><pubmed_authors>Tonby K</pubmed_authors><pubmed_authors>Jenum S</pubmed_authors><pubmed_authors>Dyrhol-Riise AM</pubmed_authors><pubmed_authors>Louet C</pubmed_authors><pubmed_authors>Jorgensen MJ</pubmed_authors><pubmed_authors>Nore KG</pubmed_authors><pubmed_authors>Gidon A</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Cyclooxygenase 2 Inhibitor Etoricoxib as Adjunctive Therapy in Tuberculosis Impairs Macrophage Control of Mycobacterial Growth.</name><description>&lt;h4>Background&lt;/h4>Current tuberculosis treatment regimens could be improved by adjunct host-directed therapies (HDT) targeting host responses. We investigated the antimycobacterial capacity of macrophages from patients with tuberculosis in a phase 1/2 randomized clinical trial (TBCOX2) of the cyclooxygenase-2 inhibitor etoricoxib.&lt;h4>Methods&lt;/h4>Peripheral blood mononuclear cells from 15 patients with tuberculosis treated with adjunctive COX-2i and 18 controls (standard therapy) were collected on day 56 after treatment initiation. The ex vivo capacity of macrophages to control mycobacterial infection was assessed by challenge with Mycobacterium avium, using an in vitro culture model. Macrophage inflammatory responses were analyzed by gene expression signatures, and concentrations of cytok</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-07-05T03:15:24.473Z</modification><creation>2026-07-05T03:11:20.828Z</creation></dates><accession>S-EPMC10938220</accession><cross_references><pubmed>37721470</pubmed><doi>10.1093/infdis/jiad390</doi></cross_references></HashMap>